Evidence map›Paper›PMID 34259962›Full record

ArticleCellular and molecular neurobiology2022

Decreased Glucose Metabolism and Glutamine Synthesis in the Retina of a Transgenic Mouse Model of Alzheimer's Disease.

Anna Luna Mølgaard Tams, Berta Sanz-Morello, Emil Winther Westi, Zaynab Ahmad Mouhammad, Jens Velde Andersen, Kristine Karla Freude, Rupali Vohra, Jens Hannibal, Blanca Irene Aldana, Miriam Kolko

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Potential Retinal Biomarkers in Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Disruption of Glucose Metabolism in AgedFrontiers in integrative neuroscience · 2021
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Anna Luna Mølgaard Tams *Eye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Berta Sanz-Morello *Eye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Emil Winther WestiNeurometabolism Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Zaynab Ahmad MouhammadEye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Jens Velde AndersenNeurometabolism Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Kristine Karla FreudeGroup of Stem Cells and Modeling of Neurodegeneration, Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.
Rupali VohraEye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Jens HannibalDepartment of Clinical Biochemistry, Bispebjerg Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.
Blanca Irene AldanaNeurometabolism Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. blanca.aldana@sund.ku.dk.
Miriam KolkoEye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. miriamk@sund.ku.dk.ORCID http://orcid.org/0000-0001-8697-0734
University of Copenhagen · DK

Funding

Beckett-Fonden 19-2-4285Hørslev-Fonden 203866-MAS/mbs1Novo Nordisk Fonden NNF18SA0034956
6 · The paper itself

Abstract

Visual changes are some of the earliest symptoms that patients with Alzheimer's disease (AD) experience. Pathophysiological processes such as amyloid-β plaque formation, vascular changes, neuroinflammation, and loss of retinal ganglion cells (RGCs) have been detected in the retina of AD patients and animal models. However, little is known about the molecular processes that underlie retinal neurodegeneration in AD. The cellular architecture and constant sensory activity of the retina impose high metabolic demands. We thus hypothesized that energy metabolism might be compromised in the AD retina similarly to what has been observed in the AD brain. To address this question, we explored cellular alterations and retinal metabolic activity in the 5 × FAD mouse model of AD. We used 8-month-old female 5 × FAD mice, in which the AD-related pathology has been shown to be apparent. We observed that RGC density is selectively affected in the retina of 5 × FAD mice. To map retinal metabolic activity, we incubated isolated retinal tissue with [U-

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalFemaleGlucoseGlutamineHumansMiceMice, TransgenicRetinaAmyloid beta-Protein PrecursorGlucoseGlutamineAlzheimer's diseaseCellular metabolismNeurodegenerationRetinaRetinal ganglion cells

Identifiers

PMID34259962
PMCPMC11441235
OpenAlexW3182269943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.